The National Institute of Allergy and Infectious Diseases (NIAID) has issued clinical guidelines recommending introduction of peanut-containing foods during infancy to limit the risk of developing peanut allergy. Published Jan. 5, 2017 in the Journal of Allergy and Clinical Immunology, the new NIAID Addendum Guidelines for the Prevention of Peanut Allergy in the United States… Continue reading New NIAID Guidelines Recommend Peanut-Containing Foods for Infants to Prevent Peanut Allergy
The FARE Clinical Network is expanding, and will now comprise 28 centers of excellence across the country. The FARE Clinical Network, dedicated to changing the face of food allergy care, is the only collaborative network of its kind. Five centers have recently joined the network, which now comprises 28 centers of excellence across the country.… Continue reading New Centers of Excellence Join the FARE Clinical Network
Younger brothers and sisters of peanut-allergic children are at higher risk for peanut sensitivity than children in general. However, a Canadian study published in the June 2016 issue of Allergy found that siblings whose peanut allergy tests were negative prior to introduction did not have an allergic response when they ate peanut for the first… Continue reading In Siblings, Peanut Tolerance Is Predicted by Negative Test Results Prior to Introduction
FARE recently received the Eugene Washington Engagement Award from the Patient-Centered Outcomes Research Institute (PCORI). FARE’s two-year project, “Empowering Patient Partners and Key Stakeholders to Develop a Patient-Centric Food Allergy Research Program,” seeks to address an unmet need in the research field by forming a partnership of patients empowered to work with other key stakeholders… Continue reading Interested in Providing the Patient Perspective in Research?
Earlier this month, FARE staff members attended the annual scientific meeting of the American Academy of Allergy, Asthma & Immunology, where researchers presented a number of new abstracts. Of interest to the food allergy community, both Aimmune Therapeutics and DBV Technologies presented new findings during the session for late-breaking abstracts. Aimmune Therapeutics Aimmune reported data… Continue reading Report from AAAAI: Aimmune and DBV Technologies Present New Findings
Epinephrine should be prescribed for all patients at risk of experiencing a severe reaction (anaphylaxis). Epinephrine is the only medication that can reverse the symptoms of anaphylaxis. Recent findings from poster presentations given at the annual meeting of the American Academy of Allergy, Asthma & Immunology reiterate the importance of having this life-saving medication available and… Continue reading New Findings on Epinephrine Availability and Use in Schools
Many children outgrow their food allergies as they reach their teenage or adult years. A food that used to cause a reaction by the immune system in a negative way is now neutral; the food is tolerated. A new study published in the January 28, 2016, online issue of Science by La Jolla Institute for Allergy… Continue reading New Insights on How Children Develop Allergies and Why Some Outgrow Them